What is KeyCorp’s Forecast for Solventum FY2027 Earnings?

Solventum Corporation (NYSE:SOLV) – Analysts at KeyCorp boosted their FY2027 earnings estimates for shares of Solventum in a report issued on Sunday, January 25th. KeyCorp analyst B. Fishbin now expects that the company will earn $6.90 per share for the year, up from their previous estimate of $6.88. KeyCorp currently has a “Overweight” rating and a $97.00 target price on the stock. The consensus estimate for Solventum’s current full-year earnings is $6.58 per share.

SOLV has been the subject of a number of other reports. UBS Group reissued a “neutral” rating on shares of Solventum in a research report on Friday, November 21st. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Piper Sandler reiterated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Finally, Stifel Nicolaus increased their price target on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $90.83.

Solventum Stock Performance

Shares of SOLV stock opened at $76.60 on Tuesday. The stock’s 50-day moving average is $81.70 and its two-hundred day moving average is $75.78. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.14 and a current ratio of 1.50. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The firm has a market cap of $13.29 billion, a price-to-earnings ratio of 8.83, a PEG ratio of 7.12 and a beta of 0.34.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same period last year, the business earned $1.64 EPS. Solventum’s revenue for the quarter was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS.

Solventum declared that its board has initiated a stock buyback program on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 7.5% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its stock is undervalued.

Hedge Funds Weigh In On Solventum

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after buying an additional 867,837 shares during the last quarter. Independent Franchise Partners LLP increased its stake in shares of Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock worth $941,645,000 after acquiring an additional 2,758,174 shares during the period. State Street Corp raised its holdings in Solventum by 1.8% during the third quarter. State Street Corp now owns 6,220,271 shares of the company’s stock worth $454,080,000 after purchasing an additional 112,261 shares in the last quarter. Davis Selected Advisers lifted its position in Solventum by 0.5% in the third quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock valued at $402,786,000 after purchasing an additional 24,950 shares during the period. Finally, Boston Partners lifted its position in Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the period.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.